Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Phase 3

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: Atezolizumab
Drug: Enzalutamide

First Posted Date: 2017-01-10

Last Posted Date: 2024-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 759

Registration Number: NCT03016312

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸
City of Hope Medical Grp Inc., Duarte, California, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

and more 155 locations

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Anti-TNF-alpha
Drug: Methotrexate
Drug: Placebo
Drug: RO7123520

First Posted Date: 2016-12-22

Last Posted Date: 2020-01-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 109

Registration Number: NCT03001219

Locations: 🇨🇴
Servimed S.A.S., Bucaramanga, Colombia
🇲🇽
Investigacion y Biomedicina de Chihuahua, Sociedad Civil, Chichuahua, Chihuahua, Mexico
🇲🇽
Centro Médico de las Américas, Merida, Yucatan, Mexico

and more 77 locations

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Phase 2

Completed

Conditions: Bladder Cancer
Pancreas Cancer
Cholangiocellular Carcinoma

Interventions: Drug: Trastuzumab Emtansine

First Posted Date: 2016-12-21

Last Posted Date: 2019-08-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 20

Registration Number: NCT02999672

Locations: 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇮🇹
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy
🇸🇰
Narodny onkologicky ustav, Bratislava, Slovakia

and more 13 locations

Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Renodapt
Drug: Mycept
Drug: Cellmune
Drug: CellCept

First Posted Date: 2016-12-05

Last Posted Date: 2016-12-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT02981290

Locations: 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: RO7079901

First Posted Date: 2016-11-29

Last Posted Date: 2017-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT02975388

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: RO7079901
Other: RO7049389 Placebo
Other: Meropenem Placebo
Drug: Meropenem

First Posted Date: 2016-11-23

Last Posted Date: 2017-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT02972255

Locations: 🇺🇸
Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Phase 1

Completed

Conditions: Hepatitis B, Chronic

Interventions: Other: Placebo
Drug: RO7020531

First Posted Date: 2016-11-06

Last Posted Date: 2024-02-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 160

Registration Number: NCT02956850

Locations: 🇳🇱
Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU University Medical Center, Amsterdam, Netherlands
🇧🇬
Gastroenterology department, Second clinic of internal diseases, Sofia, Bulgaria
🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

and more 15 locations

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

Completed

Conditions: Breast Cancer

First Posted Date: 2016-11-03

Last Posted Date: 2019-09-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 351

Registration Number: NCT02954471

Locations: 🇸🇦
King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia
🇸🇦
King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia
🇸🇦
National Guard King Abdulaziz Medical City; Oncology, Riyadh, Saudi Arabia

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Basmisanil

First Posted Date: 2016-11-03

Last Posted Date: 2021-02-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 214

Registration Number: NCT02953639

Locations: 🇺🇸
Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

and more 34 locations

Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Device: Smartphone and Smartwatch

First Posted Date: 2016-11-02

Last Posted Date: 2019-02-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT02952911

Locations: 🇪🇸
Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain
🇺🇸
UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy